Abstract
A pilot project offering voluntary heterozygote screening for the ΔF508 mutation causing cystic fibrosis (CF) to 638 pregnant women attending two antenatal clinics in the eastern part of Berlin was carried out from 1990–1993. Participation was invited using an information leaflet and inclusion in the study was conditional on written informed consent. Of those invited to participate, only one refused to be tested, on the grounds of non-acceptance of prenatal diagnosis. Eighteen pregnant women were identified as carriers of the ΔF508 mutation. All of them and their male partners accepted counselling in which the genetics of CF, its prognosis and treatment were explained, with emphasis on the meaning of heterozygosity, the fact that carriers are healthy, and the risk of an affected fetus when only one parent is identified as a heterozygote. All partners agreed to be tested for the ΔF508 R553X and G551D mutations and a second counselling session was carried out after this test result was available. No problems were observed during initial testing but, as in other studies, we found considerable anxiety on being given the result in all couples where the woman tested positive; this was reduced substantially by counselling and when the partner tested negative. All probands found to be carriers stated that they found screening acceptable. In contrast to the cautious statement by the German Berufsverband Medizinische Genetik and the hostile reaction from a representative of the CF self-support organisation towards community-based heterozygote screening for CF, this study shows that CF screening is generally acceptable in this German population and that it is actively taken up by most pregnant women when offered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Society of Human Genetics (1992) Statement of the American Society of Human Genetics on Cystic Fibrosis Carrier Screening. Am J Hum Genet 51:1179–1186
Berufsverband Medizinische Genetik (1990) Stellungnahme zu einem möglichen Heterozygoten-Screening bei Cystischer Fibrose. Med Genet 2/3:6–7
Bilas (1990) Richtlinien zur Durchführung molekulargenetischer diagnostischer Leistungen - Stellungnahme zu einem m6glichen Heterozygotenscreening bei Cystischer Fibrose (Korrespondenz). Med Genetik 2:37
Bremer W (1990) Heterozygotenscreening. Klopfzeichen 1:8–11
Coutelle C, Bruckner R, Grade K, Behrens F, Gedschold J, Hein J, Szibor R, Bauer I, Brock J, Graupner I, Urner U, Leucht B (1992) Prevalence of cystic fibrosis mutations in the East German population. Hum Mutat 1:109–112
Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui L-C, Antonarakis SE, Kazazian HH (1990) A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 346:366–369
Decruyenacre M, Evers-Kiebooms G, Denayer L, Van den Berghe H (1992) Cystic fibrosis community knowledge and attitudes towards carrier screening and prenatal diagnosis. Clin Genet 41:189–196
Gille C, Grade K, Coutelle C (1991) A pooling strategy for heterozygote testing of the DeltaF508 cystic fibrosis mutation. Hum Genet 86:289–291
Green JM (1992) Principles and practicalities of carrier screening: attitudes of recent parents. J Med Genet 29:315–319
Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA, Brock DJH (1992) Prenatal screening for cystic fibrosis. Lancet 340:214–216
Mennie ME, Compton ME, Gilfillan A, Liston WA, Pullen I, Whyte DA, Brock DJH (1993) Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners. J Med Genet 340:214–216
Modell B (1990) Cystic fibrosis screening and community genetics. J Med Genet 27:475–479
Rommens J, Kerem B, Greer W, Chiang P, Tsui L-C, Ray P (1990) Rapid nonradioactive detection of the major CF-mutation. Am J Hum Genet 46:395–396
Schwartz M, Brandt NJ, Skovby F (1993) Screening for carriers of cystic fibrosis among pregnant women: a pilot study. Eur J Hum Genet 1:239–244
Shuber AP, Skoletasky J, Stern R, Handelin BL (1993) Efficient 12-mutation testing in the CFTR gene: a general model for complex mutation analysis. Hum Mol Genet 2:153–158
Ten Kate LP, Tijmstra T (1990) Community attitudes to cystic fibrosis carrier screening. Prenat Diagn 10:275–276
Walsh PS, Metzger DA, Higuchi R (1991) Chelex 100 as a medium for simple extraction of DNA for PCR-based typing for forensic material. Biotechniques 10:506–513
Watson EK, Mayall E, Chapple J, Dalziel M, Harrington K, Williams C, Williamson R (1991) Screening for carriers of cystic fibrosis through primary health care services. BMJ 303:504–507
Watson EK, Mayall ES, Lamb J, Chapple J, Williamson R (1992) Psychological and social consequences of community carrier screening programme for cystic fibrosis. Lancet 340:217–220
Williamson R, Allison MED, Bentley TJ, Lim SMC, Watson E, Chapple J, Adam S, Boulton M (1989) Community attitudes to cystic fibrosis carrier testing in England: A pilot study. Prenatal Diag 9:727–734
Williamson R (1993) Universal carrier screening for cystic fibrosis? Nature Genetics
Witt DR, Blumberg B, Schaefer C, Fitzgerald P, Fishbach A, Holtzmann J, Kornfeld S, Lee R, Nemzer L, Palmer R, Sato M, Jenkins L (1992) Cystic fibrosis carrier screening in a prenatal population. Am J Hum Genet 51: (Suppl) Abstract 55 A 16
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jung, U., Urner, U., Grade, K. et al. Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population. Hum Genet 94, 19–24 (1994). https://doi.org/10.1007/BF02272835
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02272835